ReviewMolecular diagnosis & therapy2020

Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.

Simoneide S Titze-de-Almeida et al.PubMed ↗Publisher ↗

No numbers read from the abstract.